0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. "Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance," Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 20, 2025 03:43 ET (07:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.